A Phase II Study of Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma
Inclusion Criteria:
- There is no evidence of metastatic disease in the major viscera and no peritoneal
seeding
- Patients with biliary or gastroduodenal obstruction must have drainage prior to
starting chemoradiation
- All malignant disease must be encompassable within a single irradiation field
(15x15cm maximum)
- All patients must have radiographically assessable disease
- No previous irradiation to the planned field
- Age of ≥18 years
- performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score
- Required Entry Laboratory Parameters WBC count ≥ 2,000/mm3;(ANC>1,000), hemoglobin
level ≥ 7.5 g/dL; platelet count ≥ 100,000/mm3; total bilirubin ≤ 3.0 mg/dL (Patients
with elevated bilirubin due to obstruction should be stented and their bilirubin
should be decreas ≤ 3.0 mg/dL prior to study entry); creatinine ≤ 3.0 mg/dL
- Oral intake (including J-tube feeding) of ≥ 1,500 calories/day should be maintained.
Exclusion Criteria:
- There is evidence of metastasis in the major viscera or peritoneal seeding.
- Age of <18 years
- Previous history of RT adjacent to planned field
- poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG)
score
- pregnant or breast feeding status
- previous history of uncontrolled other malignancies within 2 years